Ces radiol. 2013, 67(1):35-38

Progressive multifocal leukoencephalopathy in patient with multiple sclerosis treated by natalizumabCase report

Ivana Štětkářová1, Eva Medová1, Veronika Bučilová1, Josef Vymazal2
1 Neurologická klinika 3. LF UK a FNKV, Praha
2 Radiologické oddělení Nemocnice Na Homolce, Praha

Natalizumab (monoclonal antibody) is currently indicated as a second line treatment for relapse-remitting multiple sclerosis (RR-MS). Serious and potential fatal side effect of this treatment is progressive multifocal leukoencefalopathy (PML), which belongs to rare brain infections caused by JC virus (JCV). There is a progressive inflammation of the brain white matter in multiple localizations. A high risk of developing PML includes serum JCV positivity, previous immunosuppressive treatment and duration of natalizumab treatment of more than two years. Magnetic resonance is one of the most important diagnostic methods because it can identify brain damage in the early stage of the disease.
We present 47-years-old female with RR-MS which has been successfully treated by natalizumab for three years with very good clinical outcome. In last year of treatment, patient experienced a seizure and in later stages progressive deterioration of cognitive function and severe quadriplegia. Positive JCV was found in cerebrospinal fluid. MR presented diffuse hyperintensive lesions located in frontal lobes. Despite immediate discontinuation of natalizumab treatment and subsequent daily plasma-exchange PML disease progressed and patient died within two months of the final diagnosis.
PML is a serious complication of natalizumab treatment in multiple sclerosis. It is important to recognize early signs and symptoms of this disease. Therefore, it is necessary clinically and morphologically monitor the patients in high risk of PML with repeated MR (especially flair sequence) to prevent fatal complication.

Keywords: multiple sclerosis, natalizumab, progressive multifocal leukoencefalopathy, JC virus
Grants and funding:

Práce byla podpořena výzkumným projektem Univerzity Karlovy PRVOUK P34.

Accepted: September 15, 2012; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štětkářová I, Medová E, Bučilová V, Vymazal J. Progressive multifocal leukoencephalopathy in patient with multiple sclerosis treated by natalizumab. Ces radiol. 2013;67(1):35-38.
Download citation

References

  1. Bergsland N, Horakova D, Dwyer MG, et al. Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. AJNR Am J Neuroradiol 2012; 33(8): 1573-1578. Go to original source... Go to PubMed...
  2. Polman CH, O'Connor PW, Havrdova E, et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910. Go to original source... Go to PubMed...
  3. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9(4): 438-446. Go to original source... Go to PubMed...
  4. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumabmonotherapy. N Engl J Med 2009; 361(11): 1081-1087. Go to original source... Go to PubMed...
  5. Weber T. Progressive Multifocal Leukoencephalopathy. Neurol Clin 2008; 26(3): 833-854. Go to original source... Go to PubMed...
  6. Agostini HT, Ryschkewitsch CF, Stoner GL. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol 1996; 34: 159-164. Go to original source... Go to PubMed...
  7. Kitamura T, Aso Y, Kuniyoshi N, et al. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 1990; 161: 1128-1133. Go to original source... Go to PubMed...
  8. Dörries K, Sbiera S, Drews K, et al. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol 2003; 9(Suppl 1): 81-87. Go to original source... Go to PubMed...
  9. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18(2): 143-152. Go to original source... Go to PubMed...
  10. Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009; 15(1): 28-35. Go to original source... Go to PubMed...
  11. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 2012; 71(7): 604-617. Go to original source... Go to PubMed...
  12. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012; 83(2): 224-226. Go to original source... Go to PubMed...
  13. Schröder A, Lee DH, Hellwig K, et al. Successful management of natalizumab-associated progressive multifocal leukoencefalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010; 67(11): 1391-1394. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.